X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRS-060/AZD-1402 (elarekibep) is Pieris’ lead respiratory Anticalin®-based drug candidate and an inhaled IL-4 receptor alpha inhibitor, under development for the treatment of asthma.
Lead Product(s): Elarekibep
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRS-060
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
PRS-060 (elarekibep) blocks the IL-4Ralpha immunoreceptor, inhibiting small IL-4 and IL-13 proteins that drive a cascade of inflammatory responses in the lungs. It is being developed for the treatment of moderate-to-severe asthma.
Lead Product(s): Elarekibep
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRS-060
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2023
Details:
Under the terms of the agreement, Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342. Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the IND-enabling stage.
Lead Product(s): PRS-342
Therapeutic Area: Oncology Product Name: PRS-342
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boston Pharmaceuticals
Deal Size: $363.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement April 26, 2021
Details:
Pieris' option to co-develop and co-commercialize the second of 3 programs in the collaboration has been amended to provide it with a co-promotion option in the U.S, with Seagen solely responsible for the development and overall commercialization of that program.
Lead Product(s): Cinrebafusp alfa,Tucatinib
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Seagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2021
Details:
U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.
Lead Product(s): PRS-343
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2021
Details:
Lilly to supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year.
Lead Product(s): PRS-343,Ramucirumab,Paclitaxel
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2020
Details:
Company will present phase 1 dose-escalation monotherapy and combination with atezolizumab data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in an oral presentation session at the European Society for Medical Oncology Congress 2020.
Lead Product(s): PRS-343,Atezolizumab
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
The partial hold follows discussions with FDA regarding the Company's in-use study supporting the technical setup for clinical administration of PRS-343.
Lead Product(s): PRS-343,Atezolizumab
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
